Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491.

Levy G, Carillo S, Papoular B, Cassinat B, Zini JM, Leroy E, Varghese LN, Chachoua I, Defour JP, Smith SO, Constantinescu SN.

Blood. 2020 Mar 19;135(12):948-953. doi: 10.1182/blood.2019003240.

PMID:
31978223
2.

Ear pain, vesicles and facial palsy.

Flamarion E, Zini J, Passeron A.

Eur J Intern Med. 2019 Dec;70:e5-e6. doi: 10.1016/j.ejim.2019.10.006. Epub 2019 Oct 29. No abstract available.

PMID:
31676202
3.

Mott cell interstitial nephritis revealing Waldenström macroglobulinaemia.

Moktefi A, Dudreuilh C, Goujon JM, Quellard N, Zini JM, Audard V, Rémy P.

Ann Hematol. 2018 Sep;97(9):1735-1736. doi: 10.1007/s00277-018-3326-5. Epub 2018 Apr 8. No abstract available.

PMID:
29629483
4.

Identification and characterization of novel enhanced cell penetrating peptides for anti-cancer cargo delivery.

Zhang X, Brossas JY, Parizot C, Zini JM, Rebollo A.

Oncotarget. 2017 Dec 11;9(5):5944-5957. doi: 10.18632/oncotarget.23179. eCollection 2018 Jan 19.

5.

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.

Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, Laribi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graczyk M, Delavigne K, Dartigeas C, Ysebaert L; French Innovative Leukemia Organization (FILO) CLL group.

Blood. 2018 Apr 26;131(17):1955-1959. doi: 10.1182/blood-2017-11-818286. Epub 2018 Feb 1.

PMID:
29437588
6.

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).

Durot E, Tomowiak C, Michallet AS, Dupuis J, Hivert B, Leprêtre S, Toussaint E, Godet S, Merabet F, Van Den Neste E, Ivanoff S, Roussel X, Zini JM, Regny C, Lemal R, Sutton L, Perrot A, Le Dû K, Kanagaratnam L, Morel P, Leblond V, Delmer A.

Br J Haematol. 2017 Nov;179(3):439-448. doi: 10.1111/bjh.14881. Epub 2017 Aug 2.

PMID:
28770576
7.

Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.

Baron M, Zini JM, Challan Belval T, Vignon M, Denis B, Alanio A, Malphettes M.

Leuk Lymphoma. 2017 Dec;58(12):2981-2982. doi: 10.1080/10428194.2017.1320710. Epub 2017 May 30. No abstract available.

PMID:
28554246
8.

Evaluation of Caspase-9b and PP2Acα2 as potential biomarkers for chronic lymphocytic leukemia.

Domínguez-Berrocal L, Zhang X, Zini JM, Fominaya J, Rebollo A, Bravo J.

Biomark Res. 2016 May 4;4:9. doi: 10.1186/s40364-016-0063-6. eCollection 2016.

9.

Idelalisib-related pneumonitis.

Haustraete E, Obert J, Diab S, Abbes S, Zini JM, Valade S, Lerolle N, Albin N, Arnulf B, Bouaziz JD, Hussenet C, Tazi A, Bergeron A.

Eur Respir J. 2016 Apr;47(4):1280-3. doi: 10.1183/13993003.01670-2015. Epub 2016 Feb 25. No abstract available.

10.

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort.

PLoS One. 2015 Aug 6;10(8):e0134904. doi: 10.1371/journal.pone.0134904. eCollection 2015.

11.

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.

Fornecker LM, Aurran-Schleinitz T, Michallet AS, Cazin B, Guieze R, Dilhuydy MS, Zini JM, Tomowiak C, Lepretre S, Cymbalista F, Brion A, Feugier P, Delmer A, Leblond V, Ysebaert L.

Am J Hematol. 2015 Jun;90(6):511-4. doi: 10.1002/ajh.23999. Epub 2015 Apr 1.

12.

Cell penetrating peptides as a therapeutic strategy in chronic lymphocytic leukemia.

Arrouss I, Decaudin D, Choquet S, Azar N, Parizot C, Zini JM, Nemati F, Rebollo A.

Protein Pept Lett. 2015;22(6):539-46.

PMID:
25687226
13.

[Urticarial vasculitis associated with essential thrombocythaemia progressing to myelofibrosis].

Koudoukpo C, Jachiet M, Zini JM, Andreoli A, Pinquier L, Rybojad M, Bosset D, de Masson A, Bagot M, Lebbé C, Bouaziz JD.

Ann Dermatol Venereol. 2014 Dec;141(12):773-6. doi: 10.1016/j.annder.2014.09.005. Epub 2014 Oct 14. French.

PMID:
25433930
14.

Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.

Deuzing IP, Charpentier C, Wright DW, Matheron S, Paton J, Frentz D, van de Vijver DA, Coveney PV, Descamps D; ANRS CO5 HIV-2 Cohort, Boucher CA, Beerens N.

J Virol. 2015 Jan;89(1):833-43. doi: 10.1128/JVI.02259-14. Epub 2014 Oct 29.

15.

Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.

Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, Levy V, Maloisel F, Re D, Zini JM, Troussard X; French Society of Haematology.

Ann Hematol. 2014 Dec;93(12):1977-83. doi: 10.1007/s00277-014-2140-y. Epub 2014 Jul 5.

16.

Transmitted drug resistance in French HIV-2-infected patients.

Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort.

AIDS. 2013 Jun 19;27(10):1671-4. doi: 10.1097/QAD.0b013e32836207f3.

PMID:
23595155
17.

Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.

Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F; French ANRS HIV-2 CO5 Cohort.

Clin Infect Dis. 2012 Nov 15;55(10):1417-25. doi: 10.1093/cid/cis708. Epub 2012 Aug 20.

PMID:
22911639
18.

Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol.

Morel P, Munck JN, Coiffier B, Gisselbrecht C, Ranta D, Bosly A, Tilly H, Quesnel B, Thyss A, Mounier N, Brière J, Molina T, Reyes F; Groupe d'Etude de Lymphomes des l'Adulte (GELA).

Leuk Lymphoma. 2010 Sep;51(9):1668-77. doi: 10.3109/10428194.2010.504871.

PMID:
20807094
19.

Disease progression in HIV-1-infected patients heterozygous for the sickle hemoglobin gene.

Sellier P, Masson E, Zini JM, Simoneau G, Magnier JD, Evans J, Bergmann JF.

AIDS. 2009 Nov 13;23(17):2362-4. doi: 10.1097/QAD.0b013e32833298a7.

PMID:
19773632
20.

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20.

PMID:
18718922

Supplemental Content

Loading ...
Support Center